Cardiff Lexington Corporation (QX) (CDIX)

Cardiff Lexington's Nova Ortho and Spine Announces New Medical Office in Stuart, Florida to Serve the Growing Treasure Coast Community

LEXINGTON, KY / ACCESS Newswire / May 20, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) ("Cardiff Lexington" or the "Company"), a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that Nova Ortho and Spine, a wholly owned subsidiary of Cardiff Lexington Corporation, has opened a new location in Stuart, Florida. This new location further strengthens Nova Ortho and Spine's expanding regional network of healthcare facilities throughout Florida and supports the organization's broader strategy of increasing accessibility to specialized orthopedic and spine services in underserved and high-growth markets.

Strategically positioned along the Federal Highway corridor with convenient access to major regional transportation routes, the newly developed 2,975-square-foot clinic expands Nova Ortho and Spine's footprint along Florida's Treasure Coast and will provide comprehensive orthopedic, spine, and musculoskeletal care services to patients throughout Stuart, Palm City, Jensen Beach, Port St. Lucie, and surrounding Martin and St. Lucie County communities. The facility is designed to provide efficient patient flow, modern clinical infrastructure, and a patient-centered care environment focused on orthopedic evaluation, spine care, diagnostics, and non-surgical treatment options.

Martin County and neighboring St. Lucie County continue to experience significant population growth, driven by both residential expansion and an increasing retiree population seeking high-quality healthcare services in South Florida. According to recent regional demographic estimates, the combined population of Martin and St. Lucie Counties now exceeds 650,000 residents, with continued growth projected over the coming decade. The Treasure Coast region also maintains one of Florida's highest concentrations of residents aged 55 and older - a demographic frequently requiring orthopedic, spine, pain management, and mobility-related healthcare services.

"We are excited to serve this growing community and proud of our exceptional clinical staff and highly experienced providers," said Dr. Kevin Fitzgerald. "The Treasure Coast continues to experience substantial population growth, and this new location allows us to expand access to high-quality orthopedic and spine care while remaining focused on delivering outstanding patient outcomes and compassionate service."

Alex H. Cunningham, Chief Executive Officer of Cardiff Lexington Corporation, added, "The opening of our Stuart location represents another important milestone in Nova Ortho and Spine's strategic growth throughout Florida. We believe the Treasure Coast region presents a strong long-term opportunity due to its continued population expansion, favorable demographics, and increasing demand for specialized musculoskeletal healthcare services. This location prioritizes patient demographics as Nova remains committed to investing in high-quality facilities, experienced providers, and scalable healthcare infrastructure designed to better serve patients and communities across the region."

The facility will provide convenient access for patients seeking evaluation and treatment for conditions involving:

Orthopedic injuries and disorders
Neck and back pain
Spine-related conditions
Musculoskeletal injuries
Joint pain and mobility issues
Personal injury-related orthopedic care
Non-surgical pain management solutions

Nova Ortho and Spine's continued expansion throughout South Florida reflects increasing patient demand for specialized musculoskeletal care and the organization's long-term commitment to investing in community-based healthcare infrastructure across the region.

Patients seeking orthopedic and spine care may contact the Stuart office directly at 772-529-4573 for additional information or to schedule an appointment. The facility is located at 701 NW Federal Highway, Ste. 101, Stuart, Florida 34994.

About Nova Ortho and Spine

Nova Ortho and Spine is a growing provider of orthopedic, spine, and musculoskeletal healthcare services focused on delivering patient-centered treatment solutions through experienced providers, advanced clinical care, and compassionate service. With multiple locations throughout Florida, Nova Ortho and Spine continues to expand access to high-quality orthopedic and spine care for the communities it serves across South Florida and the Treasure Coast region.

About Cardiff Lexington Corporation

Cardiff Lexington Corporation is a publicly traded healthcare services holding company focused on building a regional and national platform in orthopedic, spine, and pain management markets. Through its operating subsidiaries, including Nova Ortho and Spine, the Company delivers a comprehensive suite of services including diagnostics, interventional pain management, surgical coordination, and specialty care.

The Company's strategy is centered on disciplined capital deployment, operational efficiency, and scalable growth through acquisitions and strategic partnerships within highly fragmented healthcare markets.

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

SOURCE: Cardiff Lexington Corporation


View the original press release on ACCESS Newswire

https://app.accessnewswire.com/img.ashx?id=1168388

© Copyright 2026 ACCESS Newswire. All Rights Reserved.

Cardiff Lexington Announces First Quarter 2026 Financial Results

LEXINGTON, KY / ACCESS Newswire / May 19, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) today announced financial results for the first quarter ended March 31, 2026.

Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "We continue to strengthen and expand our network of Nova Ortho and Spine locations to support growing patient demand with a focus on more high value procedures, and we remain confident in our ability to build a scalable platform through organic growth and acquisitions that deliver exceptional outcomes for patients. Furthermore, our recent upgrade to the OTCQX market represents an important step in increasing our visibility and credibility among institutional investors as we execute our strategic initiatives to enhance our access to working capital and drive sustainable, long-term growth and shareholder value."

First Quarter 2026 Financial Results

Total revenue was $2.2 million compared with $2.9 million in the first quarter of 2025. The decrease in revenue is mainly attributable to a decrease in surgical procedures in the first quarter of 2026 compared to the first quarter of 2025.

Gross profit was $1.3 million, or 59.3% of total revenue, compared with $1.8 million, or 63.1% of total revenue in the first quarter of 2025.

Total operating expenses increased to $1.8 million compared with $1.3 million in the first quarter of 2025, primarily related to share based compensation of $664,000 in the first quarter of 2026, compared with no share based compensation in the first quarter of 2025. SG&A expense was $1.2 million, or 52.4% of revenue in the first quarter of 2026, compared with $1.3 million, or 43.9% of revenue in the first quarter of 2025.

Loss from continuing operations was $511,000, or (23.0%) of total revenue, in the first quarter of 2026, compared with income from continuing operations of $544,000, or 18.7% of total revenue, in the first quarter of 2025.

Net loss in the first quarter of 2026 was $3.1 million compared with net loss of $451,000 in the first quarter of 2025. Included in net loss for the three months ended March 31, 2026, was interest expense of $1.9 million compared with interest expense of $1.0 million in the first quarter of 2025. The increase in interest expense is primarily attributable to the increase in initial and incremental fees charged on the number of existing purchases and claims under the Company's line of credit.

Non-GAAP adjusted EBITDA, which excludes interest expense, was $164,000 compared with non-GAAP adjusted EBITDA of $546,000 in the first quarter of 2025.

Balance Sheet

Cash totaled $684,000 as of March 31, 2026.

Total assets increased 4.1% to $30.3 million as of March 31, 2026.

Conference Call

Cardiff Lexington will hold a conference call and webcast for investors today, May 19, 2026, at 11:00 a.m. Eastern Time.

Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 204811. The call and the accompanying slide deck will also be webcast at:

https://www.webcaster5.com/Webcast/Page/3131/53976

An online archive of the webcast will be available at the above webcast link. A replay of the conference call will be available one hour after completion of the call until Tuesday, June 2, 2026, by dialing (877) 481-4010 and international participants should dial (919) 882-2331. All callers must use access code 53976 to access the replay.

-----

About Cardiff Lexington Corporation:

Cardiff Lexington Corporation is a publicly traded healthcare services holding company focused on building a regional and national platform in orthopedic, spine, and pain management markets. Through its operating subsidiaries, including Nova Ortho and Spine, the Company delivers a comprehensive suite of services including diagnostics, interventional pain management, surgical coordination, and specialty care.

The Company's strategy is centered on disciplined capital deployment, operational efficiency, and scalable growth through acquisitions and strategic partnerships within highly fragmented healthcare markets.

FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.

Use of Non-GAAP Financial Measures

Cardiff Lexington Corporation prepares its consolidated financial statements in accordance with United States generally accepted accounting principles ("GAAP"). In addition to GAAP disclosures, this document contains financial information and measures considered to be "non-GAAP". These non-GAAP measures can be used in order to gain a more complete and accurate understanding of the Company's financial condition and results. Non-GAAP financial measures should be considered in conjunction with, and not as a substitute to GAAP financial measures.

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2026, AND 2025




For the Three Months Ended






March 31,






March 31,






2026






2025


Total revenue




$


2,222,280






$


2,915,567


Total cost of sales






904,225








1,075,034


Gross profit






1,318,055








1,840,533


Operating expenses
















Depreciation expense






593








3,365


Loss on disposal of fixed assets






0








12,593


Stock compensation expense






664,196








0


Selling, general and administrative






1,164,425








1,280,641


Total operating expenses






1,829,214








1,296,599


(Loss) income from continuing operations






(511,159


)






543,934


















Other (expense) income:
















Other income (expense)






10,081








(1,597


)
Loss from issuance/change in value of derivative liability






(668,821


)






0


Interest expense






(1,910,737


)






(993,114


)
Amortization of debt discounts






(11,438


)






0


Total other expense






(2,580,915


)






(994,711


)
















Net loss




$


(3,092,074


)




$


(450,777


)

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF MARCH 31, 2026, AND DECEMBER 31, 2025




March 31,






December 31,






2026






2025


ASSETS












Current assets












Cash




$


683,507






$


318,535


Accounts receivable, net






22,890,899








22,070,954


Prepaid and other current assets






282,747








203,876


Total current assets






23,857,153








22,593,365


















Property and equipment, net






2,360








2,953


Land






540,000








540,000


Goodwill






5,666,608








5,666,608


Right of use - assets






155,237








214,858


Due from related party






4,979








4,979


Other assets






64,371








64,182


Total assets




$


30,290,708






$


29,086,945


















LIABILITIES, MEZZANINE EQUITY AND DEFICIENCY IN STOCKHOLDERS' (DEFICIT)/EQUITY
















Current liabilities
















Accounts payable and accrued expense




$


1,779,073






$


1,760,765


Accrued expenses - related parties






237,277








4,645,826


Accrued interest






730,866








707,574


Right of use - operating lease liability






143,937








178,524


Notes payable - current portion






50,745








125,774


Notes payable related parties - current portion






1,085,703








1,085,703


Line of credit






18,922,173








17,209,908


Convertible notes payable, net of debt discounts of $815,228 and $131,705,
respectively






279,772








118,295


Derivative liability






1,129,345








0


Total current liabilities






24,358,891








25,832,369


















Other liabilities
















Operating lease liability - long term






17,366








42,976


Notes payable






137,934








138,773


Notes payable related parties






116,667








0


Total liabilities






24,630,858








26,014,118


















Mezzanine equity
















Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares
authorized, $0.001 par value, stated value $4.00, 1,068,004 and 1,037,311
shares issued and outstanding at March 31, 2026 and December 31, 2025,
respectively






0








3,802,010


Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares
authorized, $0.001 par value, stated value of $4.00; 449,117 and 438,388
shares issued and outstanding at March 31, 2026 and December 31, 2025,
respectively






1,783,394








1,740,478


Total Mezzanine Equity






1,783,394








5,542,488


















Stockholders' (deficit)/equity
















Series F-1 Preferred Stock - 50,000 shares authorized, $0.001 par value,
stated value $4.00, 3,875 shares issued and outstanding at March 31, 2026
and December 31, 2025






15,500








15,500


Series L Preferred Stock - 400,000 shares authorized, $0.001 par value,
stated value $4.00, 319,493 shares issued and outstanding at March 31, 2026
and December 31, 2025






1,277,972








1,277,972


Series N Senior Convertible Preferred Stock - 3,000,000 shares
authorized, $0.001 par value, stated value $4.00, 1,068,004 and 1,037,311
shares issued and outstanding at March 31, 2026 and December 31, 2025,
respectively






3,924,782








0


Series Y Senior Convertible Preferred Stock - 1,500,000 shares authorized,
$0.001 par value, stated value of $4.00, 1,094,354 and 1,067,878 shares
issued and outstanding at March 31, 2026 and December 31 2025,
respectively






4,377,413








4,271,512


Common Stock; 300,000,000 shares authorized, $0.001 par value;
15,167,350 and 13,701,698 shares issued and outstanding at March 31, 2026
and December 31, 2025, respectively






15,167








13,702


Additional paid-in capital






77,453,073








72,021,848


Unearned stock compensation






(331,938


)






(579,215


)
Accumulated deficit






(82,855,513


)






(79,490,980


)
Total stockholders' equity/(deficit)






3,876,456








(2,469,661


)
Total liabilities, mezzanine equity and stockholders' equity




$


30,290,708






$


29,086,945


CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE MONTHS ENDED MARCH 31, 2026, AND 2025
(Unaudited)

The following table reconciles Net income (loss) before discontinued operations (a GAAP financial measure) to EBITDA and Adjusted EBITDA (non-GAAP financial measures)




For the Three Months Ended






March 31,






2026






2025


EBITDA (1)












Net loss before discontinued operations




$


(3,092,074


)




$


(450,777


)
Add:
















Interest






1,910,737








993,114


Taxes






0








0


Depreciation






593








3,365


Amortization






11,438








0


















EBITDA (1)




$


(1,169,306


)




$


545,702


















Adjusted EBITDA (2)
















EBITDA




$


(1,169,306


)




$


545,702


Add:
















Derivative loss upon issuance and changes in the liability






668,821








0


Stock compensation expense for shares issued






664,196








0


































Adjusted EBITDA (2)




$


163,711






$


545,702


































Adjusted EBITDA excluding other non-recurring costs (3)
































Adjusted EBITDA




$


163,711






$


545,702


Add:
















Scaling and restructuring costs for business growth






14,762








0


Acquisition related costs






79,153








56,635


















Adjusted EBITDA excluding other non-recurring costs (3)




$


257,626






$


602,337


















(1) EBITDA is a non-GAAP financial measure defined as Earnings Before Interest, Income Tax, Depreciation and Amortization.

(2) Adjusted EBITDA is a non-GAAP financial measure that is the sum of EBITDA plus non-recurring and non-cash charges.

(3) Adjusted EBITDA excluding other non-recurring costs is a non-GAAP financial measure that is the sum of Adjusted EBITDA plus other non-recurring costs.

SOURCE: Cardiff Lexington Corporation


View the original press release on ACCESS Newswire

https://app.accessnewswire.com/img.ashx?id=1167971

© Copyright 2026 ACCESS Newswire. All Rights Reserved.

Cardiff Lexington to Report First Quarter 2026 Financial Results and Host Conference Call on Tuesday, May 19, 2026

LEXINGTON, KY / ACCESS Newswire / May 14, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that the Company will host an investor conference call to discuss its financial and operating results for the first quarter ended March 31, 2026, on Tuesday, May 19, 2026, at 11:00 am ET.

The Company will release its financial and operating results for the first quarter ended March 31, 2026, prior to the call on Tuesday, May 19, 2026.

Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 204811. The call and the accompanying slide deck will also be webcast at:

https://www.webcaster5.com/Webcast/Page/3131/53976

An online archive of the webcast will be available at the above webcast link. A replay of the conference call will be available one hour after completion of the call until Tuesday, June 2, 2026, by dialing (877) 481-4010 and international participants should dial (919) 882-2331. All callers must use access code 53976 to access the replay.

About Cardiff Lexington Corporation:

Cardiff Lexington Corporation is a publicly traded healthcare services holding company focused on building a regional and national platform in orthopedic, spine, and pain management markets. Through its operating subsidiaries, including Nova Ortho and Spine, the Company delivers a comprehensive suite of services including diagnostics, interventional pain management, surgical coordination, and specialty care.

The Company's strategy is centered on disciplined capital deployment, operational efficiency, and scalable growth through acquisitions and strategic partnerships within highly fragmented healthcare markets.

FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.

Cardiff Lexington Investor Relations
investorrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

SOURCE: Cardiff Lexington Corporation


View the original press release on ACCESS Newswire

https://app.accessnewswire.com/img.ashx?id=1166790

© Copyright 2026 ACCESS Newswire. All Rights Reserved.

Cardiff Lexington Corporation Announces Upgrade to OTCQX Best Market

LEXINGTON, KY / ACCESS Newswire / April 9, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) ("Cardiff Lexington" or the "Company"), a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that its common stock has been approved to trade on the OTCQX® Best Market, the highest-level market of the OTC Markets, effective at the commencement of trading on Thursday, April 9th, 2026. The Company will continue to trade under the symbol "CDIX".

The OTCQX Best Market is designed for established, investor-focused companies and requires high financial standards, strong corporate governance, and compliance with applicable securities laws.

Strategic Positioning and Market Advancement

Upgrading to OTCQX from the OTCQB® Venture Market reflects Cardiff Lexington's continued commitment to enhanced transparency and maintaining the highest governance and financial reporting standards available to companies trading on the OTC Markets.

"We view our upgrade to the OTCQX Best Market as a meaningful milestone in Cardiff Lexington's evolution as a disciplined, growth-oriented healthcare platform," said Alex H. Cunningham, Chief Executive Officer of Cardiff Lexington Corporation. "This transition strengthens our visibility within the institutional investor community and reinforces our commitment to building a scalable, high-margin healthcare enterprise with a clear path toward a national exchange listing. Listing on a national exchange would significantly enhance access to working capital to support increased patient volume and procedural throughput without relying on higher-cost financing structures and accelerate our accounts receivable conversion cycles. We look forward to leveraging this enhanced OTCQX visibility alongside our high-margin operating model to drive sustainable revenue growth, expand margins, and enhance long-term shareholder value."

Demonstrated Financial Performance and Operating Leverage

Cardiff Lexington has demonstrated consistent financial growth and operating performance driven by its focused healthcare platform strategy. For the fiscal year ended December 31, 2025, the Company reported:

Revenue of approximately $11.5 million compared with $8.3 million in full year 2024, representing a 39.5% increase
Gross profit increased to $7.2 million, or 62.5% of total revenue, compared with $4.4 million, or 53.6% of total revenue in full year 2024.
Operating income increased to $1.1 million, or 9.5% of total revenue, compared with operating loss of $(193,000), or (2.3%) of total revenue, in full year 2024.
Total assets increased 21.6% to $29.1 million as of December 31, 2025

This performance reflects a high-margin operating model within the orthopedic and spine care sector and underscores management's focus on scalable, capital-efficient growth.

Execution of Proven Three-Pillar Growth Strategy

Cardiff Lexington continues to execute on its differentiated three-pillar strategy, designed to drive sustainable revenue growth, expand margins, and enhance long-term shareholder value:

Core Cash Flow Platform - Acquisition and optimization of physician orthopedic and related practices to generate consistent, recurring revenue streams
Asset Acquisition - Strategic acquisition of ambulatory surgery centers (ASCs), MRI Clinics, and clinic real estate to enhance operating leverage and asset-backed value
Finance Strategy - Retention and management of personal injury-related accounts receivable to maximize long-term cash yield versus discounted third-party sales

This integrated approach has enabled the Company to establish a high-margin operating model within a fragmented and supply-constrained healthcare segment, positioning it for disciplined expansion through both organic growth and targeted acquisitions in one of the most resilient segments of U.S. Healthcare that offers an exceptional balance of downside protection, sustainable profitability, and scalable growth.

Working Capital Expansion and Operational Scaling

The Company's operating platform, anchored by its subsidiary Nova Ortho and Spine, continues to experience strong demand across its markets and currently operates below full capacity primarily due to working capital constraints rather than clinical or operational limitations.

Cardiff Lexington is actively pursuing strategic initiatives to:

Expand working capital to support increased patient volume and procedural throughput
Reduce reliance on higher-cost financing structures
Accelerate accounts receivable conversion cycles
Enhance overall EBITDA generation and cash flow visibility

Cardiff Lexington has demonstrated and proven the ability to deploy capital at a very high rate of return. Management believes that improving access to cost-efficient growth capital will allow the Company to materially increase utilization rates and unlock embedded operating leverage across its platform.

Alignment with Uplisting Strategy

The OTCQX upgrade represents an important step in Cardiff Lexington's broader capital markets strategy, which includes pursuing a future uplisting to a national securities exchange, such as the NYSE American or Nasdaq Capital Market, subject to meeting applicable listing requirements.

"We believe our progression to OTCQX appropriately reflects the maturation of our business and strengthens our positioning as we evaluate strategic capital formation opportunities and a potential uplisting," Cunningham added.

Investor Information

Investors can find current financial disclosure and real-time Level 2 quotes for the Company on www.otcmarkets.com.

No action is required by current shareholders in connection with this upgrade.

About Cardiff Lexington Corporation

Cardiff Lexington Corporation is a publicly traded healthcare services holding company focused on building a regional and national platform in orthopedic, spine, and pain management markets. Through its operating subsidiaries, including Nova Ortho and Spine, the Company delivers a comprehensive suite of services including diagnostics, interventional pain management, surgical coordination, and specialty care.

The Company's strategy is centered on disciplined capital deployment, operational efficiency, and scalable growth through acquisitions and strategic partnerships within highly fragmented healthcare markets.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company's growth strategy, capital markets plans, working capital initiatives, and potential uplisting. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update these statements except as required by law.

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

SOURCE: Cardiff Lexington Corporation


View the original press release on ACCESS Newswire

https://app.accessnewswire.com/img.ashx?id=1154758

© Copyright 2026 ACCESS Newswire. All Rights Reserved.

Cardiff Lexington Announces Fourth Quarter and Full Year 2025 Financial Results

39.5% increase in FY25 total revenue to $11.5 million compared to FY 2024
62.7% increase in FY25 gross profit to $7.2 million compared to FY 2024
$1.1 million in income from continuing operations in FY 2025
Strengthening operational team and capital structure to position Company for next phase of growth

LEXINGTON, KY / ACCESS Newswire / March 16, 2026 / Cardiff Lexington Corporation (OTCQB:CDIX) today announced financial results for the fourth quarter and full year ended December 31, 2025.

Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "2025 was a year of strong strategic execution as we continued to enhance our Nova Ortho and Spine footprint and offerings while making meaningful progress on our long-term goals. Notably, full year revenue increased 39.5% on a GAAP basis in 2025 compared with 2024, supported by our operations in numerous diverse locations throughout Florida and Georgia where we are seeing strong demand for our services. Operationally, we've shifted our focus to more higher value surgical procedures, and our patient volumes continue to increase, with an average of between 270 and 375 patients treated per month across all our locations.

"During the fourth quarter, we strengthened the Nova Ortho and Spine team with the addition of leading healthcare talent and entered a strategic partnership with Doctors' Memorial Hospital in Perry, Florida to bring our leading services to patients in this area of the state. Subsequent to the close of the quarter, we improved our capital structure with the execution of a 1-for-3 reverse split as a part of our planned uplisting to a major US stock exchange. We believe this will strengthen our capital markets profile and enhance our visibility, liquidity, and access to capital to support our anticipated growth as we continue to bring our world-class care to an underserved patient population," Mr. Cunningham concluded.

Full Year 2025 Financial Highlights

Total revenue increased 39.5% to $11.5 million compared with $8.3 million in full year 2024, primarily related to higher patient volume and a shift to more higher value surgical procedures throughout the year. Revenue in full year 2024 included one-time adjustments of $2.8 million. Non-GAAP adjusted revenue, which excludes this one-time adjustment to revenue, was $11.1 million for full year 2024.

Gross profit increased to $7.2 million, or 62.5% of total revenue, compared with $4.4 million, or 53.6% of total revenue in full year 2024.

Total operating expenses increased to $6.1 million compared with $4.6 million in full year 2024, primarily related to increased SG&A expense of $5.3 million, or 46.2% of revenue, compared with $4.1 million, or 49.1% of revenue, for the full year 2024.

Operating income increased to $1.1 million, or 9.5% of total revenue, compared with operating loss of $(193,000), or (2.3%) of total revenue, in full year 2024.

Net loss in full year 2025 was $(5.5 million) compared with net loss of $(3.3 million) in full year 2024. Included in full year 2025 was interest expense of $(6.8 million) compared with interest expense of $(3.0 million) in full year 2024. This increase in interest expense is primarily related to increases in initial and incremental fees charged on the number of existing purchases and claims under the Company's line of credit.

Non-GAAP adjusted EBITDA, which excludes interest expense, was $1.8 million compared with non-GAAP adjusted EBITDA of $2.1 million in full year 2024, which excludes interest expense and the change in accounting estimate of the billing realization rate recognized in third quarter 2024.

Fourth Quarter 2025 Financial Results

Total revenue was $2.8 million compared with 3.1 million in the fourth quarter of 2024. The decrease is primarily attributed to normal variances around the collection cycle timeframe on accounts receivables, which is typically between 12 and 24 months, as well as the timing of the 2025 holiday season, which resulted in significantly reduced patient volume over the two-week period around Christmas and New Years.

Gross profit was $1.8 million, or 63.5% of total revenue, compared with $2.0 million, or 64.8% of total revenue in the fourth quarter of 2024.

Total operating expenses increased to $2.5 million compared with $1.7 million in the fourth quarter of 2024, primarily related to increased stock compensation expense of $616,000 and SG&A expense of $1.8 million, or 66.0% of revenue in the fourth quarter of 2025, compared with $1.4 million, or 46.2% of revenue in the fourth quarter of 2024.

Loss from continuing operations was $(696,000), or (25.1%) of total revenue, in the fourth quarter of 2025, compared with income from continuing operations of $332,000, or 10.6% of total revenue, in the fourth quarter of 2024.

Net loss in the fourth quarter of 2025 was $(2.7 million) compared with net loss of $(910,000) in the fourth quarter of 2024. Included in net loss for the three months ended December 31, 2025, was interest expense of $(2.2 million) compared with interest expense of $(1.2 million) in the fourth quarter of 2024. This increase in interest expense is related to increases in initial and incremental fees charged on the number of existing purchases and claims under the Company's line of credit.

Non-GAAP adjusted EBITDA, which excludes interest expense, was a loss of $(79,000) compared with non-GAAP adjusted EBITDA of $579,000 in the fourth quarter of 2024.

Balance Sheet

Cash totaled $319,000 as of December 31, 2025.

Total assets increased 21.6% to $29.1 million as of December 31, 2025.

Conference Call

Cardiff Lexington will hold a conference call and webcast for investors today, March 16, 2026, at 11:00 a.m. Eastern Time.

Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 860308. The call and the accompanying slide deck will also be webcast at:

https://www.webcaster5.com/Webcast/Page/3131/53650

The conference call and slide deck may also be accessed via the Investor Relations page of the Company's website at https://investor.cardifflexington.com/overview/default.aspx. Please allow extra time prior to the call to visit the site.

An online archive of the webcast will be available on the Investor Relations page of the Company's website following the call at https://investor.cardifflexington.com/overview/default.aspx. A replay of the conference call will be available one hour after completion of the call until Monday, March 30, 2026, by dialing (877) 481-4010 and international participants should dial (919) 882-2331. All callers must use access code 53650 to access the replay.

-----

About Cardiff Lexington Corporation:

Cardiff Lexington Corporation (OTCQB:CDIX) is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. The Company's partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance.

All current revenue is derived from Nova Ortho and Spine, LLC, which operates a network of regional specialty and ancillary orthopedic care centers across Florida and Georgia. These facilities provide traumatic injury patients with comprehensive diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultations.

For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/

FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.

Use of Non-GAAP Financial Measures

Cardiff Lexington Corporation prepares its consolidated financial statements in accordance with United States generally accepted accounting principles ("GAAP"). In addition to GAAP disclosures, this document contains financial information and measures considered to be "non-GAAP". These non-GAAP measures can be used in order to gain a more complete and accurate understanding of the Company's financial condition and results. Non-GAAP financial measures should be considered in conjunction with, and not as a substitute to GAAP financial measures.

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2025, AND 2024




For the Three Months Ended






For the Twelve Months Ended






December 31,






December 31,






December 31,






December 31,






2025






2024






2025






2024


Total revenue




$


2,772,263






$


3,120,710






$


11,535,577






$


8,270,126


Total cost of sales






1,011,387








1,099,863








4,329,330








3,841,628


Gross profit






1,760,876








2,020,847








7,206,247








4,428,498


Operating expenses
































Depreciation expense






762








3,365








5,652








13,461


Loss on disposal of fixed assets






0








0








12,593








0


Stock compensation expense






615,787








244,500








754,475








544,725


Selling, general and administrative






1,840,631








1,440,835








5,332,941








4,063,816


Total operating expenses






2,457,180








1,688,700








6,105,661








4,622,002


(Loss) income from continuing operations






(696,304


)






332,147








1,100,586








(193,504


)
































Other (expense) income:
































Other expense






0








(642


)






(22,147


)






(5,362


)
Gain on debt refinance, forgiveness and
settlement






0








0








0








78,834


Penalties and fees






0








0








(1,500


)






(1,330


)
Interest expense






(2,228,102


)






(1,241,847


)






(6,822,816


)






(3,045,504


)
Amortization of debt discounts






0








0








0








(24,821


)
Total other expense






(2,228,102


)






(1,242,489


)






(6,846,463


)






(2,998,183


)
Net loss before discontinued operations






(2,924,406


)






(910,342


)






(5,745,877


)






(3,191,687


)
Income (loss) from discontinued operations






238,285








0








238,285








(111,312


)
































Net loss




$


(2,686,121


)




$


(910,342


)




$


(5,507,592


)




$


(3,302,999


)

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF DECEMBER 31, 2025, AND DECEMBER 31, 2024




December 31,






December 31,






2025






2024


ASSETS












Current assets












Cash




$


318,535






$


1,188,185


Accounts receivable-net






22,070,954








15,934,490


Prepaid and other current assets






203,876








89,901


Total current assets






22,593,365








17,212,576


















Property and equipment, net






2,953








21,198


Land






540,000








540,000


Goodwill






5,666,608








5,666,608


Right of use - assets






214,858








406,950


Due from related party






4,979








4,979


Other assets






64,182








73,368


Total assets






29,086,945








23,925,679


















LIABILITIES, MEZZANINE EQUITY AND DEFICIENCY IN STOCKHOLDERS' (DEFICIT)/EQUITY
















Current liabilities
















Accounts payable and accrued expense






1,760,765








1,379,760


Accrued expenses - related parties






4,645,826








4,553,057


Accrued interest






707,574








429,200


Right of use - liability






178,524








223,330


Notes payable - current portion






125,774








312,180


Notes payable related parties






1,085,703








0


Line of credit






17,209,908








8,645,991


Convertible notes payable, net of debt discounts of $131,705
and $24,821, respectively






118,295








105,000


Net liabilities of discontinued operations






0








238,285


Total current liabilities






25,832,369








15,886,803


















Other liabilities
















Notes payable






138,773








251,725


Operating lease liability - long term






42,976








185,877


Total liabilities






26,014,118








16,324,405


















Mezzanine equity
















Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value $4.00, 1,037,311 and 921,636 shares issued and outstanding at December 31, 2025 and 2024, respectively






3,802,010








3,339,317


Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares authorized, $0.001 par value, stated value of $4.00 par value; 438,388 and 397,464 shares issued and outstanding at December 31, 2025 and 2024, respectively






1,740,478








1,576,788


Total Mezzanine Equity






5,542,488








4,916,105


















Stockholders' (deficit)/equity
















Series B Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value of $4.00, 0 and 1,279,867 shares issued and outstanding at December 31, 2025 and 2024, respectively






0








5,119,468


Series C Preferred Stock - 500 shares authorized, $0.001 par value, stated value of $4.00, 0 and 74 shares issued and outstanding at December 31, 2025 and 2024, respectively






0








296


Series E Preferred Stock - 1,000,000 shares authorized, $0.001 par value, stated value $4.00, 0 and 175,375 shares issued and outstanding at December 31, 2025 and 2024, respectively






0








701,500


Series F-1 Preferred Stock - 50,000 shares authorized, $0.001 par value, stated value $4.00, 3,875 shares issued and outstanding at December 31, 2025 and 2024






15,500








15,500


Series I Preferred Stock - 15,000,000 shares authorized, $0.001 par value, stated value $4.00, 0 and 10,469,092 issued and outstanding at December 31, 2025 and 2024, respectively






0








41,876,368


Series L Preferred Stock - 400,000 shares authorized, $0.001 par value, stated value $4.00, 319,493 shares issued and outstanding at December 31, 2025 and 2024






1,277,972








1,277,972


Series Y Senior Convertible Preferred Stock - 1,500,000 shares authorized, $0.001 par value, stated value of $4.00, 1,067,878 and 979,125 shares issued and outstanding at December 31 2025 and 2024, respectively






4,271,512








3,916,500


Common Stock; 300,000,000 shares authorized, $0.001 par value; 13,701,698 and 15,300,475 shares issued and outstanding at December 31, 2025 and 2024, respectively






13,702








15,300


Additional paid-in capital






72,021,848








22,711,350


Unearned stock compensation






(579,215


)






0


Accumulated deficit






(79,490,980


)






(72,949,085


Total stockholders' (deficit)/equity






(2,469,661


)






2,685,169


Total liabilities, mezzanine equity and stockholders' equity






29,086,945








23,925,679


CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2025, AND 2024
(Unaudited)

The following table reconciles Net (loss) income before discontinued operations (a GAAP measure) to EBITDA (a non-GAAP measure)




For the Three Months Ended






For the Twelve Months Ended






December 31,






December 31,






2025






2024






2025






2024


EBITDA (1)
























Net loss before discontinued operations




$


(2,924,406


)




$


(910,342


)




$


(5,745,877


)




$


(3,191,687


)
Add:
































Interest






2,228,102








1,241,847








6,822,816








3,045,504


Taxes






0








0








0








0


Depreciation






762








3,365








5,652








13,461


Amortization






0








0








0








24,821


































EBITDA (1)




$


(695,542


)




$


334,870






$


1,082,591






$


(107,901


)
































Adjusted EBITDA (2)
































EBITDA




$


(695,542


)




$


334,870






$


1,082,591






$


(107,901


)
Add:
































Change in estimate for settlement realization rate






0








0








0








1,650,474


Stock compensation expense for shares issued






615,787








244,500








754,475








544,725


































































Adjusted EBITDA (2)




$


(79,755


)




$


579,370






$


1,837,066






$


2,087,298


































































Adjusted EBITDA excluding other non-recurring costs (3)
































































Adjusted EBITDA




$


(79,755


)




$


579,370






$


1,837,066






$


2,087,298


Add:
































Scaling and restructuring costs for business growth






473,804








39,752








485,480








220,053


Acquisition related costs






59,256








30,581








230,771








30,581


































Adjusted EBITDA excluding other non-recurring costs (3)




$


453,305






$


649,702






$


2,553,317






$


2,337,932


(1) EBITDA is a non-GAAP financial measure defined as Earnings Before Interest, Income Tax, Depreciation and Amortization.
(2) Adjusted EBITDA is a non-GAAP financial measure that is the sum of EBITDA plus non-recurring and non-cash charges.
(3) Adjusted EBITDA excluding other non-recurring costs is a non-GAAP financial measure that is the sum of Adjusted EBITDA plus other non-recurring costs.

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF REVENUE FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2025, AND 2024

The following table reconciles Revenue (a GAAP financial measure) to Adjusted Revenue (non-GAAP financial measures)
































For the Three Months Ended December 31,




For the Twelve Months Ended December 31,






2025




2024




2025




2024




















GAAP Revenue




$


2,772,263




$


3,120,710




$


11,535,577




$


8,270,126


Adjustments to Claim Settlement Realization Rate






-






-






-






2,849,629


Non-GAAP Adjusted Revenue




$


2,772,263




$


3,120,710




$


11,535,577




$


11,119,755


SOURCE: Cardiff Lexington Corporation


View the original press release on ACCESS Newswire

https://app.accessnewswire.com/img.ashx?id=1147847

© Copyright 2026 ACCESS Newswire. All Rights Reserved.

$CDIX Cardiff Lexington Subsidiary Nova Ortho and Spine Announces New Healthcare Hires to Support Growth https://investor.cardifflexington.com/news/news-details/2026/Cardiff-Lexington-Subsidiary-Nova-Ortho-and-Spine-Announces-New-Healthcare-Hires-to-Support-Growth/default.aspx

Cardiff Lexington Subsidiary Nova Ortho and Spine Announces New Healthcare Hires to Support Growth

LEXINGTON, KY / ACCESS Newswire / February 26, 2026 / Cardiff Lexington Corporation (OTCQB:CDIX), a healthcare holding company with deep leadership and operational expertise in Orthopedics, Spine Care, and Pain Management, today announced that the Company's subsidiary, Nova Ortho and Spine, LLC, has expanded its Florida team with the hiring of two highly qualified procedurally trained and certified nurse practitioners to support increased patient volume and demand throughout the region. These hires demonstrate Cardiff Lexington's ongoing commitment to providing best-in-class healthcare to patient populations throughout Florida, and the continued execution of the Company's growth strategy for Nova Ortho and Spine.

Catherine Amanda Kelly, MSN, APRN, FNP-BC, brings 20 years of clinical experience across procedural, emergency and hospital medicine that should contribute to the growth of Nova Ortho and Spine in Orlando and the Southeastern regions of Florida.

Ashley Logan, APRN- BC, has an extensive background in neurosurgery, orthopedic surgery and pain management. Her experience with procedure medicine, imaging and symptomology evaluations makes her a valuable addition to Nova Ortho and Spine, and her operational expertise will help to significantly improve efficiency, safety and overall patient satisfaction.

Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "We're very pleased to enhance our team at Nova Ortho and Spine with two highly qualified nurse practitioners with deep experience in the surgical and pain management fields. These new hires support the ongoing growth of Nova Ortho and Spine and the increasing patient volumes that we continue to see throughout Florida. We remain committed to expanding our healthcare footprint with the goal of providing best-in-class healthcare to patient populations throughout the state."

Dr. Kevin Fitzgerald, Chief Medical Officer of Nova Ortho and Spine, commented, "We're excited to officially welcome Catherine and Ashley to the Nova Ortho and Spine team. Their medical and operational expertise have played an integral role in supporting the increasing patient volume that we're seeing across our network of locations as demand for our services continues to grow."

About Cardiff Lexington Corporation

Cardiff Lexington Corporation (OTCQB:CDIX) is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. The Company's partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance.

All current revenue is derived from Nova Ortho and Spine, LLC, which operates a network of regional specialty and ancillary orthopedic care centers across Florida and Georgia. These facilities provide traumatic injury patients with comprehensive diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultations.

For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates, and projections and involve risks and uncertainties that could cause actual results to differ materially. Cardiff Lexington Corporation undertakes no obligation to update or revise forward-looking statements except as required by law.

Investor Contact

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

SOURCE: Cardiff Lexington Corporation


View the original press release on ACCESS Newswire

https://app.accessnewswire.com/img.ashx?id=1141776

© Copyright 2026 ACCESS Newswire. All Rights Reserved.

$CDIX News: Cardiff Lexington Subsidiary Nova Ortho and Spine Announces New Healthcare Hires to Support Growth
Cardiff Lexington Corporation
Thu, February 26, 2026 at 8:00 AM EST

LEXINGTON, KY / ACCESS Newswire / February 26, 2026 / Cardiff Lexington Corporation (OTCQB:CDIX), a healthcare holding company with deep leadership and operational expertise in Orthopedics, Spine Care, and Pain Management, today announced that the Company's subsidiary, Nova Ortho and Spine, LLC, has expanded its Florida team with the hiring of two highly qualified procedurally trained and certified nurse practitioners to support increased patient volume and demand throughout the region. These hires demonstrate Cardiff Lexington's ongoing commitment to providing best-in-class healthcare to patient populations throughout Florida, and the continued execution of the Company's growth strategy for Nova Ortho and Spine.

Catherine Amanda Kelly, MSN, APRN, FNP-BC, brings 20 years of clinical experience across procedural, emergency and hospital medicine that should contribute to the growth of Nova Ortho and Spine in Orlando and the Southeastern regions of Florida.

Ashley Logan, APRN- BC, has an extensive background in neurosurgery, orthopedic surgery and pain management. Her experience with procedure medicine, imaging and symptomology evaluations makes her a valuable addition to Nova Ortho and Spine, and her operational expertise will help to significantly improve efficiency, safety and overall patient satisfaction.

Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "We're very pleased to enhance our team at Nova Ortho and Spine with two highly qualified nurse practitioners with deep experience in the surgical and pain management fields. These new hires support the ongoing growth of Nova Ortho and Spine and the increasing patient volumes that we continue to see throughout Florida. We remain committed to expanding our healthcare footprint with the goal of providing best-in-class healthcare to patient populations throughout the state."

Dr. Kevin Fitzgerald, Chief Medical Officer of Nova Ortho and Spine, commented, "We're excited to officially welcome Catherine and Ashley to the Nova Ortho and Spine team. Their medical and operational expertise have played an integral role in supporting the increasing patient volume that we're seeing across our network of locations as demand for our services continues to grow."

About Cardiff Lexington Corporation

Cardiff Lexington Corporation (OTCQB:CDIX) is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. The Company's partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance.

All current revenue is derived from Nova Ortho and Spine, LLC, which operates a network of regional specialty and ancillary orthopedic care centers across Florida and Georgia. These facilities provide traumatic injury patients with comprehensive diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultations.

For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates, and projections and involve risks and uncertainties that could cause actual results to differ materially. Cardiff Lexington Corporation undertakes no obligation to update or revise forward-looking statements except as required by law.

Investor Contact

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

SOURCE: Cardiff Lexington Corporation

Cardiff Lexington Corporation Engages Investment Bank to Lead S-1 Filing and Nasdaq Uplist Strategy

LEXINGTON, KY / ACCESS Newswire / January 20, 2026 / Cardiff Lexington Corporation (OTCQB:CDIXD) ("Cardiff" or the "Company"), a healthcare holding company with deep leadership and operational expertise in Orthopedics, Spine Care, and Pain Management, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock.

The number of shares to be offered and the price range for the proposed offering have not yet been determined. The public offering is subject to market and other conditions. The Company intends to list its common stock on The Nasdaq Capital Market under the symbol "CDIX."

The Company has engaged R. F. Lafferty & Co., Inc. as its sole bookrunning manager for the proposed offering. Completion of the uplisting remains subject to SEC effectiveness of the Registration Statement, approval by Nasdaq, and satisfaction of all applicable listing requirements. Under the engagement terms, R. F. Lafferty & Co., Inc. will provide strategic advisory services covering market strategy, capital formation, valuation, investor positioning, and regulatory readiness.

"This marks an important step in strengthening our capital-markets strategy and positioning Cardiff Lexington for its next phase of disciplined growth," said Alex H. Cunningham, Chief Executive Officer. "Our orthopedics, spine care, and pain management business provides an invaluable service to underserved patients in one of the fastest growing and most resilient segments of U.S. healthcare. By uplisting to Nasdaq, we intend to enhance liquidity, expand access to investors, and support the scalable platform we continue to build and acquire. We look forward to working closely with R. F. Lafferty & Co., Inc. as we execute this next phase."

"This engagement reflects our commitment to transparency, operational excellence, and sustained value creation," added Matthew T. Shafer, CPA, MBA, Senior Vice President, Chief Financial Officer, and Treasurer. "We look forward to working closely with R. F. Lafferty & Co., Inc. as we work to execute our financial and strategic roadmap."

Board Member Statements

Gillard B. Johnson III, Independent Director and Audit Committee Chairman stated: "The Board is unified in its support of this strategic transition. Cardiff Lexington is operating in a high-growth sector with strong underlying fundamentals, and the Company is positioning itself for long-term institutional acceptance. Pursuing a Nasdaq listing demonstrates our commitment to governance, transparency, and disciplined growth."

L. Jack Staley, Independent Director and Compensation Committee Chair, added: "Engaging a respected investment bank is a meaningful step toward unlocking the Company's full market potential. A Nasdaq listing would increase visibility, strengthen our capital-markets profile, and support expansion in one of the strongest segments of the healthcare services economy. Cardiff Lexington is well-positioned to benefit from the stability and scale that a national exchange listing provides."

Cathy Pennington, Independent Director, commented: "This is an important milestone for Cardiff Lexington and for the patients and providers we serve. Our commitment to building a high-quality, sustainable healthcare platform is reflected in every strategic decision we make, including this step toward seeking a Nasdaq listing to attract top-tier partners, and drive long-term value for shareholders."

The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from R. F. Lafferty & Co., Inc. via email: Offerings@rflafferty.com, or by standard mail at R. F. Lafferty & Co., Inc., 40 Wall Street, Suite 3602, New York, NY10005. In addition, a copy of the final prospectus, when available, relating to the offering may be obtained via the SEC's website at www.sec.gov.

A registration statement on Form S-1 (File No. 333-) was filed with the Securities and Exchange Commission on December 15, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

AboutR. F. Lafferty & Co., Inc.

Established in 1946, R.F. Lafferty & Co., Inc. is a global, full-service broker-dealer headquartered in New York, New York. R.F. Lafferty has been family owned and operated since 1970, and clients can expect exceptional experience, continuity in service and true dedication from the people they work with at R.F. Lafferty. R.F. Lafferty offers an array of customized services including retail brokerage, wealth management, institutional sales and trading, market making, independent research, and investment banking.

About Cardiff Lexington Corporation

Cardiff Lexington Corporation (OTCQB:CDIX) is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. The Company's partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance.

All current revenue is derived from Nova Ortho and Spine, LLC, which operates a network of regional specialty and ancillary orthopedic care centers across Florida and Georgia. These facilities provide traumatic injury patients with comprehensive diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultations.

For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/

Disclaimer:

This article is provided for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or investment strategy. The views expressed in the article are those of the original source and do not necessarily reflect the views of RF Lafferty & Co. Inc. Past performance is not indicative of future results. Investors should consult their financial advisor and review all relevant disclosures before making any investment decisions.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates, and projections and involve risks and uncertainties that could cause actual results to differ materially. Cardiff Lexington Corporation undertakes no obligation to update or revise forward-looking statements except as required by law.

Investor Contact

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

SOURCE: Cardiff Lexington Corporation


View the original press release on ACCESS Newswire

https://app.accessnewswire.com/img.ashx?id=1128711

© Copyright 2026 ACCESS Newswire. All Rights Reserved.

01/09/2026 12:15:00
Reverse Split / CUSIP Change
01/12/2026 00:00:00
CDIX
CARDIFF LEXINGTON CORP COM PAR $ DEC 2023
OTC Equity

$CDIX Cardiff Lexington Announces Planned Retirement of Daniel Thompson as Chairman of the Board of Directors https://seekingalpha.com/pr/20349689-cardiff-lexington-announces-planned-retirement-of-daniel-thompson-as-chairman-of-the-board-of

$CDIX "Our presence at Doctor's Memorial Hospital reinforces our commitment to providing best-in-class, accessible healthcare to the underserved and more rural areas around Florida," Alex Cunningham, CEO of Cardiff Lexington, commented. "This region has struggled to provide effective medical care to its patients, so when Doctor's Memorial Hospital reached out to Nova Ortho and Spine, we quickly mobilized to bring our leading pain management and orthopedic and spinal surgical procedures to Taylor County. We're very pleased to be providing critical medical care for these patients and look forward to expanding our footprint into additional areas where we can further enhance healthcare standards and practices."

$CDIX News: Cardiff Lexington Subsidiary Nova Ortho and Spine Performs First Procedures at Doctor's Memorial Hospital in Perry, Florida
December 11, 2025

LEXINGTON, KY / ACCESS Newswire / December 11, 2025 / Cardiff Lexington Corporation (OTCQB:CDIX), a healthcare holding company with deep leadership and operational expertise in Orthopedics, Spine Care, and Pain Management, today announced that the Company's subsidiary, Nova Ortho and Spine, performed its first procedures at Doctor's Memorial Hospital in Perry, Florida, demonstrating Cardiff Lexington's ongoing commitment to providing best-in-class healthcare to severely underserved and rural patient populations throughout the state of Florida.

Doctor's Memorial Hospital is located in Taylor County, which according to health outcomes data, ranks among the lowest counties in Florida in terms of health factors and outcomes. Taylor County is significantly underserved with a very high healthcare provider to patient ratio while the frequency of certain procedures and treatments is higher than the Florida state average. Moreover, community feedback has identified an overwhelming need for more healthcare providers including specialty physicians.

"Our presence at Doctor's Memorial Hospital reinforces our commitment to providing best-in-class, accessible healthcare to the underserved and more rural areas around Florida," Alex Cunningham, CEO of Cardiff Lexington, commented. "This region has struggled to provide effective medical care to its patients, so when Doctor's Memorial Hospital reached out to Nova Ortho and Spine, we quickly mobilized to bring our leading pain management and orthopedic and spinal surgical procedures to Taylor County. We're very pleased to be providing critical medical care for these patients and look forward to expanding our footprint into additional areas where we can further enhance healthcare standards and practices."

Dr. Marc Brodsky, Medical Administration Director of Nova Ortho and Spine, commented, "Nova Ortho and Spine is committed to providing the very best in healthcare, and we're energized by the opportunity to be partnering with Doctor's Memorial Hospital to offer our services to a severely undeserved population. Establishing a presence in Taylor County is a logical next step in Nova Ortho and Spine's growth."

Dr. Kevin Fitzgerald, Managing Medical Director of Nova Ortho, and Spine, commented, "Nova Ortho and Spine has a very strong reputation as a provider of exceptional pain management, orthopedic, and spine care services, and we're pleased to be bringing those operational capabilities, as well as our expertise and experience to the patients of Doctor's Memorial Hospital."

About Cardiff Lexington Corporation

Cardiff Lexington Corporation (OTCQB:CDIX) is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. The Company's partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance.

All current revenue is derived from Nova Ortho and Spine, LLC, which operates a network of regional specialty and ancillary orthopedic care centers across Florida and Georgia. These facilities provide traumatic injury patients with comprehensive diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultations.

For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates, and projections and involve risks and uncertainties that could cause actual results to differ materially. Cardiff Lexington Corporation undertakes no obligation to update or revise forward-looking statements except as required by law.

Investor Contact

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

$CDIX Cardiff Lexington Subsidiary Nova Ortho and Spine Performs First Procedures at Doctor's Memorial Hospital in Perry, Florida https://finance.yahoo.com/news/cardiff-lexington-subsidiary-nova-ortho-134500119.html

Cardiff Lexington Subsidiary Nova Ortho and Spine Performs First Procedures at Doctor's Memorial Hospital in Perry, Florida

LEXINGTON, KY / ACCESS Newswire / December 11, 2025 / Cardiff Lexington Corporation (OTCQB:CDIX), a healthcare holding company with deep leadership and operational expertise in Orthopedics, Spine Care, and Pain Management, today announced that the Company's subsidiary, Nova Ortho and Spine, performed its first procedures at Doctor's Memorial Hospital in Perry, Florida, demonstrating Cardiff Lexington's ongoing commitment to providing best-in-class healthcare to severely underserved and rural patient populations throughout the state of Florida.

Doctor's Memorial Hospital is located in Taylor County, which according to health outcomes data, ranks among the lowest counties in Florida in terms of health factors and outcomes. Taylor County is significantly underserved with a very high healthcare provider to patient ratio while the frequency of certain procedures and treatments is higher than the Florida state average. Moreover, community feedback has identified an overwhelming need for more healthcare providers including specialty physicians.

"Our presence at Doctor's Memorial Hospital reinforces our commitment to providing best-in-class, accessible healthcare to the underserved and more rural areas around Florida," Alex Cunningham, CEO of Cardiff Lexington, commented. "This region has struggled to provide effective medical care to its patients, so when Doctor's Memorial Hospital reached out to Nova Ortho and Spine, we quickly mobilized to bring our leading pain management and orthopedic and spinal surgical procedures to Taylor County. We're very pleased to be providing critical medical care for these patients and look forward to expanding our footprint into additional areas where we can further enhance healthcare standards and practices."

Dr. Marc Brodsky, Medical Administration Director of Nova Ortho and Spine, commented, "Nova Ortho and Spine is committed to providing the very best in healthcare, and we're energized by the opportunity to be partnering with Doctor's Memorial Hospital to offer our services to a severely undeserved population. Establishing a presence in Taylor County is a logical next step in Nova Ortho and Spine's growth."

Dr. Kevin Fitzgerald, Managing Medical Director of Nova Ortho, and Spine, commented, "Nova Ortho and Spine has a very strong reputation as a provider of exceptional pain management, orthopedic, and spine care services, and we're pleased to be bringing those operational capabilities, as well as our expertise and experience to the patients of Doctor's Memorial Hospital."

About Cardiff Lexington Corporation

Cardiff Lexington Corporation (OTCQB:CDIX) is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. The Company's partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance.

All current revenue is derived from Nova Ortho and Spine, LLC, which operates a network of regional specialty and ancillary orthopedic care centers across Florida and Georgia. These facilities provide traumatic injury patients with comprehensive diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultations.

For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates, and projections and involve risks and uncertainties that could cause actual results to differ materially. Cardiff Lexington Corporation undertakes no obligation to update or revise forward-looking statements except as required by law.

Investor Contact

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

SOURCE: Cardiff Lexington Corporation


View the original press release on ACCESS Newswire

https://app.accessnewswire.com/img.ashx?id=1116398

© Copyright 2025 ACCESS Newswire. All Rights Reserved.

Cardiff Lexington Announces Uplisting to OTCQB Venture Market

LEXINGTON, KY / ACCESS Newswire / May 20, 2025 / Cardiff Lexington Corporation (OTCQB:CDIX) today announced that the Company's stock has successfully uplisted and commenced trading on the OTCQB Venture Market (the "OTCQB"), effective Thursday, May 15, 2025. The Company will continue to trade under the ticker symbol "CDIX." This uplisting was achieved following a successful application and approval process to verify that Cardiff Lexington meets OTCQB listing qualifications.

Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "Uplisting to the OTCQB Venture Market represents a significant milestone for our Company and reflects our commitment to transparency, growth, and delivering long-term value to our shareholders. We have made considerable progress expanding our business and putting Cardiff Lexington on track for a record 2025 while also significantly streamlining our capital structure. This achievement enhances our visibility with investors and supports our continued momentum as we move through 2025 and beyond."

The OTCQB, operated by OTC Markets Group and recognized by the U.S. Securities and Exchange Commission (SEC) as a reputable public market for early stage and developing U.S. and internal companies, offers investors essential data to evaluate, value, and trade securities. Cardiff Lexington's inclusion in the OTC Markets Group is expected to support the expansion and diversification of its global shareholder base.

-----

About Cardiff Lexington Corporation:
Cardiff Lexington Corporation is a unique targeted healthcare holding company focused on locating, acquiring, and building middle market, niche companies, primarily in Orthopedics, Spine Care, and Pain Management. Fundamental to the Cardiff Lexington strategy is the service-based partnership culture which emphasizes core values, teamwork, accountability, and performance.

A substantial majority of the Company's revenue is derived from Nova Ortho and Spine, LLC, which operates a group of regional primary specialty and ancillary care facilities throughout Florida and Georgia that provide traumatic injury victims with a full range of diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultation services.

Cardiff Lexington trades on the OTCQB Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.

For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/

FORWARD-LOOKING STATEMENT: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

SOURCE: Cardiff Lexington Corporation


View the original press release on ACCESS Newswire

https://app.accessnewswire.com/img.ashx?id=1029639

© Copyright 2025 ACCESS Newswire. All Rights Reserved.
https://www.otcmarkets.com/stock/CDIX/news/Cardiff-Lexington-Announces-Uplisting-to-OTCQB-Venture-Market?id=477821

Went to OTCQB today

Few more million added 
Outstanding Shares19,723,96104/25/2025Restricted7,157,26204/25/2025

Supposed uplift delayed another 6 months--pending lawsuits are killing them.

50,000+ more added update Outstanding Shares15,277,47512/08/2024
Restricted2,774,07812/08/2024
Unrestricted12,503,39712/08/2024
Held at DTC2,045,63212/08/2024

Cardiff Lexington Announces Third Quarter 2024 Financial Results

LEXINGTON, KY / ACCESSWIRE / November 21, 2024 / Cardiff Lexington Corporation (OTC PINK:CDIX) announced today financial results for its third quarter and nine months ended September 30, 2024.

Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "Operationally, our business performed well during the quarter. We opened our 12th Nova Ortho and Spine location in Orlando, Florida, establishing Nova Ortho and Spine in a major metropolitan area with greater population density and higher traffic, and saw an increase in booked procedures which generally bodes well for future revenues. That said, the severe weather across Florida during the quarter has delayed many procedures. Also, our GAAP revenue was negatively impacted in the quarter due to a change in estimate related to our claim settlement realization rate that better aligns third quarter revenue with 2024 annualized rates. Adjusted revenue for the quarter, excluding this one-time change in estimate, was $3.0 million. It is our expectation that revenue will return to more historical levels going forward and grow as we strengthen our working capital to support the long-term growth of our business."

"Demand is strong, and we continue to identify strategic locations to establish new Nova Ortho and Spine offices and expand our network of healthcare services. Our shareholders' equity has grown 410% since the beginning of the year, and with our visibility today, we believe that we are on track to deliver enhanced long-term performance supported by a robust network of locations and a strong reputation as a high-quality medical care provider," Mr. Cunningham concluded.

Third Quarter 2024 Financial Results

Total revenue was $1,355,641. Revenue in the third quarter included a one-time non-cash adjustment of $1,650,474 to better align third quarter revenue with 2024 annualized claim settlement realization rates. Non-GAAP adjusted revenue, excluding the one-time non-cash adjustment, was $3,006,115
Cost of sales in the quarter increased to $1,000,601 primarily related to laboratory fees
Selling, general, and administrative expenses of $936,835 primarily related to increased salaries and wages as the Company continues to invest in its growth
Loss from continuing operations was $585,160
Non-GAAP adjusted EBITDA was $1,061,912

Nine Months 2024 Financial Results

Total revenue was $5,149,416. Revenue for the nine months ended September 30, 2024, included a one-time non-cash adjustment of $1,650,474 to better align third quarter 2024 revenue with 2024 annualized claim settlement realization rates. Non-GAAP adjusted revenue, excluding this one-time non-cash adjustment, was $6,799,890
Cost of sales for the nine-month period was $2,741,765
Selling, general, and administrative expenses of $2,622,981 primarily related to increased salaries and wages as the Company continues to invest in its growth
Loss from continuing operations was $525,651. Included in operating expenses for the nine months ended September 30, 2024 were Non-GAAP increased expenses associated with the anticipated growth of the business of $596,225
Non-GAAP Adjusted EBITDA was $1,507,928

Balance Sheet Highlights (September 30, 2024, compared to December 31, 2023)

125% increase in cash to $1,949,600
13% increase in total assets to $23,514,762
410% increase in shareholders' equity to $3,729,120

-----

About Cardiff Lexington Corporation:

Cardiff Lexington Corporation is a unique targeted healthcare holding company focused on locating, acquiring, and building middle market, niche companies, primarily in Orthopedics, Spine Care, and Pain Management. Fundamental to the Cardiff Lexington strategy is the service-based partnership culture which emphasizes core values, teamwork, accountability, and performance.

A substantial majority of the Company's revenue is derived from Nova Ortho and Spine, LLC, which operates a group of regional primary specialty and ancillary care facilities throughout Florida that provide traumatic injury victims with a full range of diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultation services.

For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/

FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.

Use of Non-GAAP Financial Measures

Cardiff Lexington Corporation prepares its consolidated financial statements in accordance with United States generally accepted accounting principles ("GAAP"). In addition to GAAP disclosures, this document contains financial information and measures considered to be "non-GAAP". These non-GAAP measures can be used in order to gain a more complete and accurate understanding of the Company's financial condition and results. Non-GAAP financial measures should be considered in conjunction with, and not as a substitute to GAAP financial measures.

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(UNAUDITED)





Unaudited






Unaudited






For the Three Months Ended






For the Nine Months Ended






September 30,






September 30,






September 30,






September 30,






2024






2023 (Restated)






2024






2023 (Restated)


Total revenue




$


1,355,641






$


3,405,859






$


5,149,416






$


9,476,764


Total cost of sales






1,000,601








551,423








2,741,765








2,589,407


Gross profit






355,040








2,854,436








2,407,651








6,887,357


Operating expenses
































Depreciation expense






3,365








3,365








10,096








11,365


Selling, general and administrative






936,835








577,677








2,622,981








2,095,611


Stock compensation expense






0








0








300,225








0


Total operating expenses






940,200








581,042








2,933,302








2,106,976


(Loss) income from continuing operations






(585,160


)






2,273,394








(525,651


)






4,780,381


































Other income (expense):
































Other (expense) income






(6,767


)






(1


)






(4,720


)






204


Gain on debt refinance, forgiveness and settlement






0








0








78,834








390


Penalties and fees






0








(16,000


)






(1,330


)






(48,000


)
Interest expense






(1,386,041


)






(226,119


)






(1,803,657


)






(1,763,698


)
Amortization of debt discounts






0








(46,048


)






(24,821


)






(94,664


)
Total other (expense) income






(1,392,808


)






(288,168


)






(1,755,694


)






(1,905,768


)
Net (loss) income before discontinued operations






(1,977,968


)






1,985,226








(2,281,345


)






2,874,613


Loss from discontinued operations






0








(3,705


)






(111,312


)






(93,005


)

































Net (loss) income




$


(1,977,968


)




$


1,981,521






$


(2,392,657


)




$


2,781,608


CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023
(UNAUDITED)





September 30,






December 31,






2024






2023 (Restated)


ASSETS












Current assets












Cash




$


1,949,600






$


866,943


Accounts receivable-net






14,798,220








13,305,254


Prepaid and other current assets






5,000








5,000


Total current assets






16,752,820








14,177,197


















Property and equipment, net






24,563








34,661


Land






540,000








540,000


Goodwill






5,666,608








5,666,608


Right of use - assets, net






465,389








289,062


Due from related party






4,979








4,979


Other assets






60,403








33,304


Total assets




$


23,514,762






$


20,745,811


















LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY
















Current liabilities
















Accounts payable and accrued expense




$


1,386,412






$


2,047,131


Accrued expenses - related parties






4,353,056








4,733,057


Accrued interest






361,172








620,963


Right of use - lease liabilities






227,606








157,669


Due to director and officer






0








120,997


Notes payable - current portion






500,826








15,977


Line of credit






7,468,971








2,120,100


Convertible notes payable, net of debt discounts of $0 and $24,820, respectively






105,000








3,807,030


Net liabilities of discontinued operations






237,643








237,643


Total current liabilities






14,640,686








13,860,567


















Other liabilities
















Notes payable






140,272








144,666


Operating lease liability - long term






236,853








119,056


Total liabilities






15,017,811








14,124,289


















Mezzanine equity
















Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value $4.00, 868,056 shares issued and outstanding at September 30, 2024 and December 31, 2023






3,230,023








3,891,439


Redeemable Series R Senior Convertible Preferred Stock - 5,000 shares authorized, $0.001 par value, stated value of $1,200, 0 and 165 shares issued and outstanding at September 30, 2024 and December 31, 2023






0








307,980


Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares authorized, $0.001 par value, stated value of $4.00 par value; 375,000 shares issued and outstanding at September 30, 2024 and December 31, 2023






1,537,808








1,690,685


Total Mezzanine Equity






4,767,831








5,890,104


















Stockholders' equity
















Series B Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value of $4.00, 753,929 and 2,139,478 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively






3,015,716








8,557,912


Series C Preferred Stock - 500 shares authorized, $0.001 par value, stated value of $4.00, 43 and 123 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively






172








492


Series E Preferred Stock - 1,000,000 shares authorized, $0.001 par value, stated value $4.00, 75,375 and 155,750 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively






301,500








623,000


Series F-1 Preferred Stock - 50,000 shares authorized, $0.001 par value, stated value $4.00, 9,500 and 35,752 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively






38,000








143,008


Series I Preferred Stock - 15,000,000 shares authorized, $0.001 par value, stated value $4.00, 11,540,500 and 14,885,000 issued and outstanding at September 30, 2024 and December 31, 2023, respectively






46,162,200








59,540,000


Series J Preferred Stock - 2,000,000 shares authorized, $0.001 par value, stated value $4.00, 0 and 1,713,584 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively






-








6,854,336


Series L Preferred Stock - 400,000 shares authorized, $0.001 par value, stated value $4.00, 319,493 shares issued and outstanding at September 30, 2024 and December 31, 2023






1,277,972








1,277,972


Series Y Senior Preferred Stock - 1,000,000 shares authorized, $0.001 par value, stated value of $4.00, 955,114 and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively






3,820,456








-


Common Stock - 300,000,000 shares authorized, $0.001 par value; 14,555,601 and 25,121 shares issued and outstanding at September 30, 2024 and December 31, 2023






14,556








25


Additional paid-in capital






20,891,337








(7,581,212


)
Accumulated deficit






(71,792,589


)






(68,684,115


)
Total stockholders' equity






3,729,120








731,418


Total liabilities, mezzanine equity and stockholders' equity




$


23,514,762






$


20,745,811


CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(UNAUDITED)

The following table reconciles Net (loss) income before discontinued operations (a GAAP measure) to EBITDA (a non-GAAP measure)




Unaudited






Unaudited






For the Three Months Ended






For the Nine Months Ended






September 30,






September 30,






2024






2023 (Restated)






2024






2023 (Restated)


EBITDA (1)
























Net (loss) income before discontinued operations




$


(1,977,968


)




$


1,985,226






$


(2,281,345


)




$


2,874,613


Add:
































Interest






1,386,041








226,119








1,803,657








1,763,698


Taxes






0








0








0








0


Depreciation






3,365








3,365








10,096








11,365


Amortization






0








46,048








24,821








94,664


































EBITDA (1)




$


(588,562


)




$


2,260,758






$


(442,771


)




$


4,744,340


































Adjusted EBITDA (2)
































EBITDA




$


(588,562


)




$


2,260,758






$


(442,771


)




$


4,744,340


Add:
































Change in estimate for settlement realization rate






1,650,474








0








1,650,474








0


Stock compensation expense for shares issued






0








0








300,225








0


































































Adjusted EBITDA (2)




$


1,061,912






$


2,260,758






$


1,507,928






$


4,744,340


































(1) EBITDA is a non-GAAP financial measure defined as Earnings Before Interest, Income Tax, Depreciation and Amortization.






























(2) Adjusted EBITDA is a non-GAAP financial measure that is the sum of EBITDA plus non-recurring and non-cash charges.






























CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF REVENUE FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024
(UNAUDITED)





Unaudited






Unaudited






For the Three Months Ended






For the Nine Months Ended






September 30, 2024






September 30, 2024














GAAP Revenue




$


1,355,641






$


5,149,416


Adjustment to Claim Settlement Realization Rate






1,650,474








1,650,474


Non-GAAP Adjusted Revenue






3,006,115








6,799,890


Contact Information

Walter Frank
Investor Relations
cardifflexington@imsinvestorrelations.com
2039729200

SOURCE: Cardiff Lexington Corporation


View the original press release on accesswire.com

© Copyright 2024 ACCESSWIRE. All Rights Reserved.
https://www.otcmarkets.com/stock/CDIX/news/story?e&id=3054537